The international pharmaceutical company Laboratorios Rubió expands its business lines by acquiring OWL Metabolomics, a biotechnology company specializing in metabolomics. This acquisition will help the company to consolidate its expansion, with pioneer diagnosis technologies and commercialization of R&D services through metabolomics.
Now part of the Rubió group, OWL Metabolomics is a biotechnology company specializing in metabolomics. It offers pioneering diagnostic products and unique R&D services to the scientific community and to the industries of human and animal health, food, nutrition, and cosmetics, among others.
This acquisition strengthens Laboratorios Rubió ability to research and develop innovative products and services, in the field of personalized medicine, facilitating the diagnosis and prognosis of diseases.
Laboratorios Rubió is an international pharmaceutical company with 100% private capital founded in 1968. Initially, the company’s mission was to market drugs unavailable in Spain at that time as they were treatments for low-prevalence diseases. Over the years, Laboratorios Rubió has invested in R&D and developed more than a dozen drugs, many of which are cutting-edge treatments for specific diseases or disorders. The company also operates in other areas of healthcare, such as diagnostics and clinical nutrition. Also, it is known for its commitment to sustainable investment in R&D. Laboratorios Rubió has agreements with leading partners in more than 60 countries and has important international certifications such as the FDA.
OWL Metabolomics, a Rubió Group company, is a pioneering biotechnology company that offers diagnostic tests with cutting-edge technologies, and R&D services to the scientific community and industry through metabolomics. The company is committed to advancing the field of diagnostic services and R&D through metabolomics, and is constantly developing new technologies to improve the quality of life of patients and contribute to scientific advances in the public and private sectors. OWL Metabolomics empowers patients to make informed decisions about their health by providing them with the information they need and helping healthcare professionals deliver personalized and effective treatments.
